



AiCuris

Anti-infective Cures

Name AiCuris GmbH & Co. KG

Address/P.O. Box Friedrich-Ebert-Str. 475 / Building 302
Postal Code/City D-42117 Wuppertal
State Germany
Contact Person Sandra Wildhagen
Telephone +49 202 317 63 0
Fax +49 202 317 63 11 77
E-Mail Address business@aicuris.com
Internet Website www.aicuris.com
Number of Employees (FTE) 55
Founded (year) 2006
Type of Laboratory S2, S3 for Anti-Infective Research and Pharmacokinetic Investigations

Areas of Activity Anti-Infectives
1. Antivirals against: Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Human Cytomegalovirus (HCMV), Human Immunodeficiency Virus (HIV)
2. Anti Bacterials against: Gram negative and Gram positive multiresistant hospital infections
3. Immune Modulation

External Collaborations Arevi Pharma, Lindopharm, Bayer HealthCare Pharmaceuticals, various contract research organisations as well as academic institutions

Request for Further Collaborations AiCuris is interested in collaborations with academic and industrial partners and pursues an active in- and outlicensing strategy

Company Overview AiCuris is a pharmaceutical company focused on the discovery, research and clinical development of novel, resistance-breaking antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.

AiCuris is dedicated to innovation in the field of anti-infective drugs. Therefore nearly all of AiCuris compounds stem from novel chemical classes and are directed against novel targets. AiCuris compounds therefore are resistance-breaking by design.

AiCuris was formed in March 2006 as a spin-out of the Anti-infectives Unit of Bayer HealthCare, well-known for its long history of successful antibiotics research which generated Ciprofloxacin and Moxifloxacin. Majority investors in AiCuris are Drs. Strüngmann, the founders and previous owners of Hexal.

The head office and laboratories of AiCuris are located at the Life Science Park in Wuppertal, Germany, where the Company occupies 3,000 square meters. Biology labs (S2 and S3) as well pharmacokinetic labs are available for the discovery and the support of the development of novel anti-infective agents.

Corporate Strategy AiCuris has core research and development expertise in Pharmacology, Microbiology, Virology, Pharmacokinetics, Medicinal Chemistry and Clinical Trials. Clinical trials and chemical work as well as CMC and Galenics are being supported by a network of external providers. AiCuris CEO is Prof. Dr. Helga Rübsamen-Schaeff, former Senior VP and Global Head of the Anti-Infectives Research at Bayer HealthCare. The members of the management combine international drug development experience from both small and large pharma companies as well as scientific expertise in anti-infectives. AiCuris thus is able to move the current portfolio through clinical development and to also discover novel therapies for infectious diseases.

The target anti-infectives market for AiCuris is composed of the antiviral market (>24 bn USD in 2011) and the antibacterial market (approx 45 bn in 2011) In this market AiCuris addresses high growth areas like virology and hospital antibiotics. One key growth driver in these markets is the rise in resistance to marketed antiviral and antibacterial agents, causing serious concern to healthcare providers and regulatory authorities worldwide. In addition, these markets show significant growth in emerging countries like China and India.

It is the intent of AiCuris to move as many compounds as possible into phase I/II and to select the ones to be offered for licensing/partnering and those for further development in house. Generally, AiCuris pursues an active in-licensing strategy for early research projects and offers selected, more advanced projects for out-licensing.

Drug Development Approach

AiCuris has a broad portfolio of compounds addressing indications with high medical need. Nearly all of AiCuris compounds offer novel mechanisms of action and stem from novel chemical classes. All compounds are resistance breaking by design.

Currently, two compounds have completed phase II and preparations for phase III are ongoing. Five agents are in phase I. Development compounds exist for the indications Human Cytomeglovirus, Herpes Simplex Virus, HIV, Hepatitis B and C, immune modulation and against multiresistant Gram negative bacteria.

In-house research-programmes address HIV and Gram positive as well as Gram negative (multi-) resistant bacterial infections. AiCuris furthermore seeks to in-license drug candidates for selected indications.

Product Pipeline

